EMILY BERTRAND: Open Payments
NPI 1194279315 · WASHINGTON, DC. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$1,643 in 85 payments from 16 companies in 2025. Trend: 2023 $1,844 · 2024 $1,443 · 2025 $1,643
Food & beverage: $1,643
| Company | Payments | Amount |
|---|---|---|
| ABBVIE INC. | 21 | $295 |
| GENZYME CORPORATION | 13 | $294 |
| Novartis Pharmaceuticals Corporation | 10 | $230 |
| Regeneron Healthcare Solutions, Inc. | 9 | $176 |
| Lilly USA, LLC | 7 | $153 |
| MAYNE PHARMA COMMERCIAL LLC | 4 | $99 |
| Almirall LLC | 5 | $96 |
| Botanix SB Inc | 4 | $85 |
| Amgen Inc. | 3 | $50 |
| SUN PHARMACEUTICAL INDUSTRIES INC. | 2 | $44 |
Products named: DUPIXENT, RINVOQ, TALTZ, COSENTYX, Seysara, SKYRIZI, SOFDRA, OTEZLA.
Industry payments across DC — which companies pay providers there.
